	US 11,920,154 B2
	Methods and compositions for feeder-free pluripotent stem cell media containing human serum
Allan J Robins, Athens, GA (US); and Thomas C Schulz, Athens, GA (US)
Assigned to ViaCyte, Inc., San Diego, CA (US)
Filed by ViaCyte, Inc., San Diego, CA (US)
Filed on Oct. 19, 2020, as Appl. No. 17/074,481.
Application 17/074,481 is a continuation of application No. 16/372,358, filed on Apr. 1, 2019, granted, now 10,808,223.
Application 16/372,358 is a continuation of application No. 15/050,069, filed on Feb. 22, 2016, granted, now 10,246,680, issued on Apr. 2, 2019.
Application 15/050,069 is a continuation of application No. 14/102,451, filed on Dec. 10, 2013, granted, now 9,267,110, issued on Feb. 23, 2016.
Application 14/102,451 is a continuation of application No. 11/875,057, filed on Oct. 19, 2007, granted, now 8,623,650, issued on Jan. 7, 2014.
Prior Publication US 2021/0047616 A1, Feb. 18, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/00 (2006.01); C12N 5/0735 (2010.01); C12N 5/071 (2010.01)

CPC C12N 5/0606 (2013.01) [C12N 5/068 (2013.01); C12N 2500/84 (2013.01); C12N 2500/98 (2013.01); C12N 2501/15 (2013.01); C12N 2506/02 (2013.01)]

9 Claims

1. An essentially feeder-free cell culture comprising:

(i) dissociated primate pluripotent stem cells in a defined medium supplemented with 0.5% to 40% human serum, and

(ii) a tissue culture vessel,

wherein the primate pluripotent stem cells and the defined medium are contained in the tissue culture vessel, and

wherein the tissue culture vessel is uncoated and free of matrix.